CRISPR/Cas9: a double-edged sword when used to combat HIV infection
© The Author(s) 2016
Received: 18 April 2016
Accepted: 18 May 2016
Published: 27 May 2016
The major barrier to eradication of HIV infection is the latent viral reservoir that persists despite long-term highly active antiretroviral therapy (HAART). The main reason for the existence of latently infected cells is that proviral DNA becomes integrated into the cellular genome. Theoretically, the elimination of proviral DNA from every infected cell should therefore be able to cure HIV infection. This concept has been tested in studies that employed designed recombinases , zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) bearing sequence-specific DNA-binding modules that recognize HIV DNA sequences . In addition, the recent development of the bacterial adaptive immune system CRISPR/Cas9 for editing of genes in mammalian cells [3, 4] quickly led to the use of this new genome editing technology to try to inhibit and eliminate infection by different viruses, including HIV-1 .
Cas9 is an endonuclease that cleaves double-stranded DNA in a sequence- specific manner. Cas9 associates with a guide RNA of which the first 20 nucleotides pair with the target DNA. In addition to this single guide RNA (sgRNA), Cas9 also needs to recognize a multi-nucleotide region that is adjacent to the 3′ end of the target DNA, which is termed PAM (protospacer adjacent motif). Several labs have designed sgRNAs to program Cas9 to cleave different regions of HIV-1 DNA that include either essential viral genes or the viral long terminal repeat (LTR). Profound suppression of HIV-1 production and infection was reported in different cell types including latently infected CD4+ T cell lines, primary CD4+ T cells and induced human pluripotent stem cells [6–11].
Despite the promising possibility that CRISPR/Cas9 could be used to inactivate or even delete proviral DNA from HIV-1 infected cells, an important unanswered question is whether and how HIV-1 might escape from the programmed CRISPR/Cas9 attack, a topic that is fundamental to attempts aimed at HIV treatment and prevention, including the use of small molecule-based antiretroviral therapy and HIV vaccines. Two recent publications by Wang G et al. 2016 and Wang Z et al. 2016 have now provided unexpected answers to these questions [12, 13].
Both groups performed HIV-1 evolution experiments in CD4+ T cells that stably expressed both Cas9 and one of several sgRNAs that target different regions of the HIV-1 genome. Although prominent virus inhibition was apparent in transient assays, all infections yielded high levels of HIV-1 production after a variable time. Rapid escape was observed when non-conserved HIV-1 sequences were attacked, but it did take longer for HIV-1 to escape from Cas9/sgRNAs that targeted the more conserved viral DNA sequences . It could be expected that HIV-1 would change the sequence of the viral DNA that is targeted by sgRNA or the PAM sequence, knowing how HIV-1 escapes from a sequence-specific RNA interference attack [14–16]. Indeed, when the targeted viral DNA regions were sequenced, mutations were identified that interfered with sgRNA recognition.
Knowing how HIV-1 acquires resistance to Cas9/sgRNA may spur the development of strategies that might overcome this unique viral escape mechanism. One solution may be to program Cas9 with multiple sgRNAs that target conserved viral DNA regions. Similar combinatorial strategies were effective for regular antiviral drugs and RNAi-mediated gene therapy to sustainably suppress viral replication . Liao et al. did show that multiplexed targeting of HIV-1 DNA led to much stronger suppression of HIV-1 infection, albeit that possible viral escape was not pursued . Another approach might involve the engineering of new Cas9 variants that are able to cleave DNA outside of the target sequence, so that the mutations arising from NHEJ repair will not prevent Cas9/sgRNA binding and DNA cleavage, thus not leading to viral resistance. Such an approach might be feasible given recent progress at creating Cas9 variants that are able to recognize different PAMs, which demonstrates the flexibility of the system [17–19]. Besides modifying Cas9, the advent of new CRISPR or CRISPR-like enzymes may also provide such a solution. For example, the newly discovered Cpf1 protein acts like Cas9, but in contrast to Cas9 that cleaves the DNA in the “seed” region adjacent to the PAM that is crucial for sgRNA recognition, Cpf1 cleaves in the more distal region of the target sequence that is less critical for sgRNA binding [20, 21]. Yet another anti-escape solution may be the suppression of the NHEJ activity, which can be achieved with anti-cancer drugs that target enzymes of the NHEJ machinery . Solutions to overcome HIV-1 resistance to CRISPR/Cas9 may also advance the application of CRISPR/Cas9 toward suppression of other viral infections.
The findings reported in these two recent studies should not impede the use of alternative CRISPR/Cas9 strategies to combat HIV infection. For example, CRISPR/Cas9 has been proposed for inactivation of the co-receptor genes CXCR4 and CCR5 to render cells refractory to HIV-1 infection [23, 24]. If HIV-1 were able to escape from such a strategy, CRISPR/Cas9 would not directly contribute to the generation of resistance mutations. It is recognized that in vivo disruption of CXCR4, rather than CCR5, may interfere with the immune function of T cells. A second example is activation of latent HIV-1 proviruses by Cas9 mutants that lack nuclease activity and that carry transcription activation domains from transcription activator proteins [25–27]. When guided by sgRNAs to the HIV-1 LTR promoter, these Cas9 variants should be able to stimulate viral gene expression and drive HIV-1 out of latency. The lack of nuclease activity would preclude these Cas9 variants from facilitating viral escape.
In addition to viral escape, several other limitations of the CRISPR/Cas9 system also warrant consideration. First, despite the fact that CRISPR/Cas9 has been shown to be effective in excision of HIV-1 proviral DNA either from acutely or latently infected cells [6–8, 10], none of these studies have tested this ability of CRISPR/Cas9 in the context of resting CD4 T cells from infected individuals. Second, we recognize that single gRNA-mediated suppression of HIV-1 replication is less pronounced compared to current therapies with small molecule inhibitors. It is possible that CRISPR/Cas9 could be combined with HAART to clear latently infected cells, which HAART on its own has been unable to achieve. Unlike antiviral drugs, CRISPR/Cas9 as a gene therapy approach has the potential to durably protect cells against HIV-1. The in vivo delivery of the CRISPR/Cas9-encoding genes might be a challenge, but the lentiviral vector system is efficient at transducing both CD4 T cells and CD34 hematopoietic stem cells. However, the integrating lentiviral vector might pose a risk of insertional oncogenesis. One recent solution to this challenge might be the use of virus-like particles that package Vpr-Cas9/sgRNA for transient delivery of this complex into target cells .
It is not readily clear whether some of these limitations of the CRISPR/Cas9 system can be overcome by switching to either the TALEN or ZFN systems. Although both the latter are more simple in that they do not have an RNA component, they are more difficult to program in terms of precise sequence specificity . Importantly, ZFN-mediated cleavage of HIV-1 DNA can also lead to the generation of resistance mutations . Nonetheless, knowledge that has been acquired using ZFN or TALEN to edit viral or cellular genes might facilitate the application of CRISPR/Cas9 in similar settings.
Recognition of the limitations of the CRISPR/Cas9 system will only advance its potential for future widespread application while suggesting strategies for improvement and optimization. The rapid progress in the CRISPR field and the discovery of new genetic tools ensures that this novel genome editing system will continue to provide surprises and excitement while leading to new and novel ways of attaining control of viral infections.
CL, MAW, ATD and BB together prepared the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
This work was supported by funding from Canadian Institutes of Health Research to C.L.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Karpinski JHI, Chemnitz J, Schäfer C, Paszkowski-Rogacz M, Chakraborty D, Beschorner N, Hofmann-Sieber H, Lange UC, Grundhoff A, Hackmann K, Schrock E, Abi-Ghanem J, Pisabarro MT, Surendranath V, Schambach A, Lindner C, van Lunzen J, Hauber J, Buchholz F. Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol. 2016;34:401–9.View ArticlePubMedGoogle Scholar
- Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol. 2012;86:8920–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science. 2013;339:823–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Price AA, Grakoui A, Weiss DS. Harnessing the prokaryotic adaptive immune system as a eukaryotic antiviral defense. Trends Microbiol. 2016;24:294–306.View ArticlePubMedGoogle Scholar
- Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep. 2013;3:2510.View ArticlePubMedPubMed CentralGoogle Scholar
- Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn J, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA. 2014;111:11461–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M, Suzuki K, Xu R, Hishida T, Chang CJ, et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun. 2015;6:6413.View ArticlePubMedGoogle Scholar
- Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, Liang C. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology. 2015;12:22.View ArticlePubMedPubMed CentralGoogle Scholar
- Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y, Karn J, Hu W, Khalili K. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci Rep. 2016;6:22555.View ArticlePubMedPubMed CentralGoogle Scholar
- Yin C, Zhang T, Li F, Yang F, Putatunda R, Young WB, Khalili K, Hu W, Zhang Y. Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS. 2016;30:1163–74.View ArticlePubMedGoogle Scholar
- Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther. 2016;24:522.PubMedPubMed CentralGoogle Scholar
- Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S, Wainberg MA, Liang C. CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep. 2016;15:1–9.View ArticleGoogle Scholar
- Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol. 2004;78:2601–5.View ArticlePubMedPubMed CentralGoogle Scholar
- ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006;14:883–92.View ArticlePubMedGoogle Scholar
- Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol. 2003;77:11531–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar VV, Zheng Z, Joung JK. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol. 2016;33:1293–8.View ArticleGoogle Scholar
- Hirano S, Nishimasu H, Ishitani R, Nureki O. Structural basis for the altered PAM specificities of engineered CRISPR-Cas9. Mol Cell. 2016;61:886–94.View ArticlePubMedGoogle Scholar
- Anders C, Bargsten K, Jinek M. Structural plasticity of PAM recognition by engineered variants of the RNA-guided endonuclease Cas9. Mol Cell. 2016;61:895–902.View ArticlePubMedGoogle Scholar
- Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163:759–71.View ArticlePubMedGoogle Scholar
- Yamano T, Nishimasu H, Zetsche B, Hirano H, Slaymaker IM, Li Y, Fedorova I, Nakane T, Makarova KS, Koonin EV, et al. Crystal structure of Cpf1 in complex with guide RNA and target DNA. Cell. 2016;165:949–62.View ArticlePubMedGoogle Scholar
- Vartak SV, Raghavan SC. Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing. FEBS J. 2016;282:4289–94.View ArticleGoogle Scholar
- Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z, Chang JC, Bao G, Muench MO, Yu J, et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA. 2014;111:9591–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M, Zhuang K, Ho W, Hou W, Huang J, Guo D. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015;5:15577.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R, Fagan PR, Putatunda R, Young WB, Khalili K, Hu W. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep. 2015;5:16277.View ArticlePubMedPubMed CentralGoogle Scholar
- Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, Planelles V, Morris KV, Weinberg MS. Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Mol Ther. 2016;24:488–98.View ArticlePubMedPubMed CentralGoogle Scholar
- Limsirichai P, Gaj T, Schaffer DV. CRISPR-mediated activation of latent HIV-1 expression. Mol Ther. 2016;24:499–507.View ArticlePubMedGoogle Scholar
- Choi JG, Dang Y, Abraham S, Ma H, Zhang J, Guo H, Cai Y, Mikkelsen JG, Wu H, Shankar P, Manjunath N. Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 2016. doi:10.1038/gt.2016.27.Google Scholar
- Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397–405.View ArticlePubMedPubMed CentralGoogle Scholar
- De Silva Feelixge HS, Stone D, Pietz HL, Roychoudhury P, Greninger AL, Schiffer JT, Aubert M, Jerome KR. Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res. 2016;126:90–8.View ArticlePubMedGoogle Scholar